Clinical Trial Update: Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) [NA]

View source ↗

Summary

Clinical trial update for a recombinant anti-CD19m-CD3 antibody injection (A-319) for acute lymphoblastic leukemia, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) (anti-CD19×anti-CD3 bispecific antibody)

Snippet

Sponsor: Shanxi Bethune Hospital | Conditions: Acute Lymphocytic Leukemia | NA | Status: NOT_YET_RECRUITING